BEIJING, China--(BUSINESS WIRE)--Avistone Biotechnology Co., Ltd (“Avistone” or “the Company”), a clinical-stage biotechnology company focused on precision oncology therapeutics, today announced results from its China and US IND enabling nonclinical studies for ANS014004 (“ANS01”), a novel small-molecule type II c-M...